Sterling Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Sterling Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.29K	Sell	782 -571	-42%	-$2.2K	﹤0.01%	2823
2026 Q1	$4.75K	Sell	1,353 -563	-29%	-$2.31K	﹤0.01%	2756
2025 Q4	$6.46K	Buy	1,916 +675	+54%	+$1.75K	﹤0.01%	2802
2025 Q3	$1.63K	Buy	1,241 +539	+77%	+$558	﹤0.01%	3010
2025 Q2	$503	Sell	702 -1,027	-59%	-$806	﹤0.01%	3153
2025 Q1	$2.54K	Sell	1,729 -1,314	-43%	-$3.13K	﹤0.01%	2497
2024 Q4	$13.5K	Buy	3,043 +2,670	+716%	+$10.8K	﹤0.01%	2021
2024 Q3	$1.54K	Buy	+373	New	+$2K	﹤0.01%	2317

Other funds holding IRWD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Sterling Capital Management's IRWD Position: Q2 2026 in Review

Sterling Capital Management reduced its Ironwood Pharmaceuticals (IRWD) stake by 42% in Q2 2026, selling an estimated $2.2K and leaving 782 shares worth $3.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2823.

Sterling Capital Management first reported a position in IRWD in Q3 2024 and has held it in 8 quarters since. The position peaked at $13.5K in Q4 2024. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

Sterling Capital Management held 782 shares of Ironwood Pharmaceuticals worth $3.29K as of Q2 2026.
Sterling Capital Management sold 571 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $2.2K.
Ironwood Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2823 holding.
Sterling Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Ironwood Pharmaceuticals position peaked at $13.5K in Q4 2024.
212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.